Jazz Pharmaceuticals Sustainability Profile
Jazz Pharmaceuticals plc, headquartered in Great Britain, is a leading biopharmaceutical company dedicated to developing innovative treatments for patients with serious conditions. Founded in 2003, Jazz has made significant strides in the industry, particularly in the areas of sleep medicine and neurology. The company’s core products, including Xyrem and Sunosi, are renowned for their unique formulations that address complex health issues such as narcolepsy and excessive daytime sleepiness. With a strong market position, Jazz Pharmaceuticals has achieved notable milestones, including strategic acquisitions that have expanded its therapeutic portfolio and global reach. Operating primarily in North America and Europe, Jazz Pharmaceuticals continues to focus on delivering high-quality, patient-centric solutions that enhance the quality of life for individuals facing challenging health conditions.
DitchCarbon Score
How does Jazz Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Jazz Pharmaceuticals's score of 28 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Jazz Pharmaceuticals's reported carbon emissions
In 2022, Jazz Pharmaceuticals, headquartered in Great Britain, reported no specific carbon emissions data, including Scope 1, 2, or 3 emissions. The company has not disclosed any reduction targets or initiatives related to carbon emissions, indicating a lack of formal commitments to reduce its carbon footprint at this time. The absence of emissions data suggests that Jazz Pharmaceuticals may be in the early stages of developing a comprehensive climate strategy. The company has not inherited any emissions data from a parent organization, and there are no reported initiatives such as SBTi targets or climate pledges that would typically guide corporate climate action. As the pharmaceutical industry increasingly prioritises sustainability, Jazz Pharmaceuticals may need to establish clear emissions reporting and reduction commitments to align with industry standards and stakeholder expectations.
How Carbon Intensive is Jazz Pharmaceuticals's Industry?
How Carbon Intensive is Jazz Pharmaceuticals's Location?
Jazz Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Jazz Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
